Regeneron Q3 revenues down 15% to $2.94B; ex-REGEN-COV up 11%; EPS $11.66

REGENERON PHARMACEUTICALS, INC.

2022-Q3 EPS reported $27.73 revenue$8,758,500,000

GAAP diluted EPS $11.66 (Q3 2021: $14.33); non-GAAP $11.14 ($15.37).
EYLEA U.S. net sales record $1.63B (+11% YoY); Dupixent global sales $2.33B (+40%).
Aflibercept 8 mg met primary endpoints in DME and wet AMD pivotal trials; BLA submission planned late 2022.
FDA granted EYLEA pediatric exclusivity through May 17, 2024; share repurchases $913M in Q3.
Full-year 2022 GAAP R&D guidance raised to $3.515-$3.600B; SG&A to $2.010-$2.090B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENERON PHARMACEUTICALS, INC. reported the quarter ended September 30, 2022 results: revenue $2.94 billion, net income $1,316 million, EPS $11.66.

Period: the quarter ended September 30, 2022
Revenue: $2.94 billion
Net income: $1,316 million
EPS: $11.66
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2022 Financial and Operating Results • Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021; excluding REGEN-COV ® (a)(b) , revenues increased 11% • Third quarter 2022 EYLEA ® U.S. net sales increased 11% versus third quarter 2021 to a record

View on SEC.gov

Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001804220-22-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.